Following this activity, participants should be able to: (1) Integrate recent advances in molecular analysis an discuss how they affect systemic therapy selection for uterine cancer. (2) Discuss how molecular profiling predictive factors can influence adjuvant radiation therapy for patients with uterine cancer. (3) Identify patients who are at high-risk and tailor treatment appropriately to provide the best long-term survival.
- Provider:National Comprehensive Cancer Network
- Activity Link: https://education.nccn.org/node/95897
- Start Date: 2024-09-10 05:00:00
- End Date: 2024-09-10 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AbbVie (Any division) - Amount: 0.0 - Is Kind Support: False Source: AstraZeneca (Any division) - Amount: 0.0 - Is Kind Support: False Source: Coherus Biosciences - Amount: 0.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 0.0 - Is Kind Support: False Source: Eisai, Inc. - Amount: 0.0 - Is Kind Support: False Source: Genentech (Any division) - Amount: 0.0 - Is Kind Support: False Source: GlaxoSmithKline - Amount: 0.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 0.0 - Is Kind Support: False Source: Novartis Corporation Pharmaceuticals - Amount: 0.0 - Is Kind Support: False Source: Pharmacyclics - Amount: 0.0 - Is Kind Support: False Source: Sanofi S.A. - Amount: 0.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest